Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: Studies with the hepatic NADPH: Cytochrome P450 reductase null (HRN) mouse model

Toxicological Sciences

Volumn 121, Issue 1, 2011, Pages 43-56

  Levová, Kateřina ^a   Moserová, Michaela ^a   Kotrbová, Věra ^a   Šulc, Miroslav ^a   Henderson, Colin J ^b   Roland Wolf, C ^b   Phillips, David H ^c   Frei, Eva ^d   Schmeiser, Heinz H ^d   Mareš, Jaroslav ^e   Arlt, Volker M ^c   Stiborová, Marie ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Aristolochic acid; Cytochrome P450; DNA adducts; Metabolism

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARCINOGEN DNA INTERACTION; CONTROLLED STUDY; DEMETHYLATION; DETOXIFICATION; ENZYME METABOLISM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY MICROSOME; LIVER MICROSOME METABOLISM; MALE; METABOLIC ACTIVATION; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN BINDING; PROTEIN FUNCTION; RAT; TURNOVER TIME;

MUS;

EID: 79955410481     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr050     Document Type: Article

References (77)

1. Arlt, V. M., Ferluga, D., Stiborova, M., Pfohl-Leszkowicz, A., Vukelic, M., Ceovic, S., Schmeiser, H. H., and Cosyns, J. P. (2002). Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int. J. Cancer. 101, 500-502.
2. Arlt, V. M., Henderson, C. J., Wolf, C. R., Schmeiser, H. H., Phillips, D. H., and Stiborova, M. (2006). Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett. 234, 220-231.
3. Arlt, V. M., Stiborova, M., Henderson, C. J., Osborne, M. R., Bieler, C. A., Frei, E., Martinek, V., Sopko, B., Wolf, C. R., Schmeiser, H. H., et al. (2005). Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res. 65, 2644-2652.
4. Arlt, V. M., Stiborova, M., Henderson, C. J., Thiemann, M., Frei, E., Aimova, D., Singh, R., Gamboa da Costa, G., Schmitz, O. J., Farmer, P. B., et al. (2008). Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 29, 656-665.
5. Arlt, V. M., Stiborova, M., Hewer, A., Schmeiser, H. H., and Phillips, D. H. (2003). Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome p450 reductase. Cancer Res. 63, 2752-2761.
6. Arlt, V. M., Stiborova, M., vom Brocke, J., Simoes, M. L., Lord, G. M., Nortier, J. L., Hollstein, M., Phillips, D. H., and Schmeiser, H. H. (2007). Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28, 2253-2261.
7. Arlt, V. M., Zuo, J., Trenz, K., Roufosse, C. A., Lord, G. M., Nortier, J. L., Schmeiser, H. H., Hollstein, M., and Phillips, D. H. (2011). Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int. J. Cancer. 128, 21-32.
8. Atanasova, S., von Ahsen, N., Toncheva, D. I., Dimitrov, T. G., Oellerich, M., and Amstrong, V. M. (2005). Genetic polymorphism of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). Clin. Biochem. 38, 223-228.
9. Bieler, C. A., Stiborová, M., Wiessler, M., Cosyns, J. P., van Ypersele de Strihou, C., and Schmeiser, H. H. (1997). 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18, 1063-1067.
10. Bořek-Dohalská, L., Hodek, P., Šulc, M., and Stiborová, M. (2001). α-Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem. Biol. Interact. 138, 85-106.
11. Bořek-Dohalská, L., and Stiborová, M. (2010). Cytochrome P450 3A activities and their modulation by a-naphthoflavone in vitro are dictated by the efficiencies of model experimental systems. Collect. Czech. Chem. Commun. 75, 201-220.
12. Buters, J. T., Sakai, S., Richter, T., Pineau, T., Alexander, D. L., Savas, U., Doehmer, J., Ward, J. M., Jefcoate, C. R., and Gonzalez, F. J. (1999). Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylben-z[a]anthracene-induced lymphomas. Proc. Natl. Acad. Sci. U.S.A. 96, 1977-1982.
13. Chan, W., Cu, L., Xu, G., and Cai, Z. (2006). Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20, 1755-1760.
14. Chan, W., Luo, H. B., Zheng, Y., Cheng, Y. K., and Cai, Z. (2007). Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats. Drug Metab. Dispos. 35, 866-874.
15. Debelle, F. D., Vanherweghem, J. L., and Nortier, J. L. (2008). Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74, 158-169.
16. Elovaara, E., Mikkola, J., Stockmann-Juvala, H., Luukkanen, L., Keski-Hynnilä, H., Kostiainen, R., Pasanen, M., Pelkonen, O., and Vainio, H. (2007). Polycyclic aromatic hydrocarbon (PAH) metabolizing enzyme activities in human lung, and their inducibility by exposure to naphthalene, phenanthrene, pyrene, chrysene, and benzo(a)pyrene as shown in the rat lung and liver. Arch. Toxicol. 81, 169-182.
17. Ernster, L. (1967). DT-Diaphorase. Methods Enzymol. 10, 309-317.
18. Grollman, A. P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., Fernandes, A., Rosenquist, T., Medverec, Z., et al. (2007). Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U.S.A. 104, 12129-12134.
19. Grosse, Y., Baan, R., Straif, K., Secretan, B., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N., Galichet, L., and Cogliano, V. (2009). A review of human carcinogens-Part A: pharmaceuticals. Lancet Oncol. 10, 13-14.
20. Henderson, C. J., Otto, D. M., Carrie, D., Magnuson, M. A., McLaren, A. W., Rosewell, I., and Wolf, C. R. (2003a). Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 278, 13480-13486.
21. Henderson, C. J., Otto, D. M., McLaren, A. W., Carrie, D., and Wolf, C. R. (2003b). Knockout mice in xenobiotic metabolism. Drug Metab. Rev. 35, 385-392.
22. Henderson, C. J., Pass, G. J., and Wolf, C. R. (2006). The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicol. Lett. 162, 111-117.
23. Henderson, C. J., and Wolf, C. R. (2003). Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology. Mol. Interv. 3, 331-343.
24. Hockley, S. L., Arlt, V. M., Brewer, D., Te Poele, R., Workman, P., Giddings, I., and Phillips, D. H. (2007). AHR-and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines. Chem. Res. Toxicol. 20, 1797-1810.
25. Hodek, P., Teplá, M., Křížková, J., and Stiborová, M. (2009). Modulation of cytochrome P450 enzyme system by flavonoid compounds. Neuro Endocrinol. Lett. 30(Suppl. 1), 67-71.
26. Kimura, S., Kawabe, M., Yu, A., Morishima, H., Fernandez-Salguero, P., Hammons, G. J., Ward, J. M., Kadlubar, F. F., and Gonzalez, F. J. (2003). Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. Carcinogenesis 24, 583-587.
27. Krumbiegel, G., Hallensleben, J., Mennicke, W. H., Rittmann, N., and Roth, H. J. (1987). Studies on the metabolism of aristolochic acids I and II. Xenobiotica 17, 981-991.
28. Lai, M. N., Wang, S. M., Chen, P. C., Chen, Y. Y., and Wang, J. D. (2010). Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J. Natl. Cancer Inst. 102, 179-186.
29. Lemy, A., Wissing, K. M., Rorive, S., Zlotta, A., Roumeguere, T., Muniz Martinez, M. C., Decaestecker, C., Salmon, I., Abramowicz, D., Vanherweghem, J. L., et al. (2008). Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am. J. Kidney Dis. 51, 471-477.
30. Lord, G. M., Cook, T., Arlt, V. M., Schmeiser, H. H., Williams, G., and Pusey, C. D. (2001). Urothelial malignant disease and Chinese herbal nephropathy. Lancet 358, 1515-1516.
31. Lord, G. M., Hollstein, M., Arlt, V. M., Roufosse, C., Pusey, C. D., Cook, T., and Schmeiser, H. H. (2004). DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43, e11-e17.
32. Mizerovská, J., Dračínská, H., Frei, E., Schmeiser, H. H., Arlt, V. M., and Stiborová, M. (2011). Induction of biotransformation enzymes by the carcinogenic air-pollutant 3-nitrobenzanthrone in liver; kidney and lung; after intra-tracheal instillation in rats. Mutat. Res. 720, 34-41.
33. Nebert, D. W. (2006). Comparison of gene expression in cell culture to that in the intact animal: relevance to drugs and environmental toxicants. Focus on "development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes". Am. J. Physiol. 290, C37-C41.
34. Nebert, D. W., and Dalton, T. P. (2006). The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer. 6, 947-960.
35. Nedelcheva, V., and Gut, I. (1994). P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24, 1151-1175.
36. Nedelko, T., Arlt, V. M., Phillips, D. H., and Hollstein, M. (2009). TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int. J. Cancer. 124, 987-990.
37. Nortier, J. L., Martinez, M. C., Schmeiser, H. H., Arlt, V. M., Bieler, C. A., Petein, M., Depierreux, M. F., De Pauw, L., Abramowicz, D., Vereerstraeten, P., et al. (2000). Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342, 1686-1692.
38. Pass, G. J., Carrie, D., Boylan, M., Lorimore, S., Wright, E., Houston, B., Henderson, C. J., and Wolf, C. R. (2005). Role of hepatic cytochrome P450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome P450 reductase null mouse. Cancer Res. 65, 4211-4217.
39. Pfau, W., Schmeiser, H. H., and Wiessler, M. (1990). Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 1, 313-319.
40. Phillips, D. H., and Arlt, V. M. (2007). The adducts. Nature Protoc. 2, 2772-2781.
41. Rendic, S., and DiCarlo, F. J. (1997). Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413-480.
42. Rolsted, K., and Kissmeyer, A. M. (2008). Evaluation of cytochrome P450 activity in vitro, using dermal and hepatic microsomes from four species and two keratinocyte cell lines in culture. Arch. Dermatol. Res. 300, 11-18.
43. Rosenquist, T. A., Einolf, H. J., Dickman, K. G., Wang, L., Smith, A., and Grollman, A. P. (2010). Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab. Dispos. 38, 761-768.
44. Schmeiser, H. H., Bieler, C. A., Wiessler, M., van Ypersele de Strihou, C., and Cosyns, J. P. (1996). Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56, 2025-2028.
45. Schmeiser, H. H., Pool, B. L., and Wiessler, M. (1984). Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett. 23, 97-101.
46. Schmeiser, H. H., Schoepe, K. B., and Wiessler, M. (1988). DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9, 297-303.
47. Schmeiser, H. H., Stiborova, M., and Arlt, V. M. (2009). Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr. Opin. Drug Discov. Devel. 12, 141-148.
48. Shibutani, S., Bonala, R. R., Rosenquist, T., Rieger, R., Suzuki, N., Johnson, F., Miller, F., and Grollman, A. P. (2010). Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer. 127, 1021-1027.
49. Simoes, M. L., Hockley, S. L., Schwerdtle, T., da Costa, G. G., Schmeiser, H. H., Phillips, D. H., and Arlt, V. M. (2008). Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. Toxicol. Appl. Pharmacol. 232, 86-98.
50. Šístková, J., Hudecek, J., Hodek, P., Frei, E., Schmeiser, H. H., and Stiborová,M. (2008). Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol. Lett. 29, 733-737.
51. Stiborová, M., Arlt, V. M., Henderson, C. J., Wolf, C. R., Kotrbova, V., Moserova, M., Hudecek, J., Phillips, D. H., and Frei, E. (2008a). Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH: cytochrome P450 reductase null mouse. Toxicol. Appl. Pharmacol. 226, 318-327.
52. Stiborová, M., Asfaw, B., Frei, E., Schmeiser, H. H., and Wiessler, M. (1995). Benzenediazonium ion derived from Sudan I forms an 8-(phenylazo)guanine adduct in DNA. Chem. Res. Toxicol. 8, 489-498.
53. Stiborová, M., Dračínská, H., Hájková, J., Kadeřábková, P., Frei, E., Schmeiser, H. H., Souček, P., Phillips, D. H., and Arlt, V. M. (2006). The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and-1A2 and NAD(P)H:quinone oxidoreductase. Drug Metab. Dispos. 34, 1398-1405.
54. 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15, 1187-1192.
55. Stiborová, M., Frei, E., Arlt, V. M., and Schmeiser, H. H. (2008b). Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 658, 55-67.
56. 32P-postlabeling analysis of DNA adduct formation. Mutat. Res. 493, 149-160.
57. Stiborová, M., Frei, E., Hodek, P., Wiessler, M., and Schmeiser, H. H. (2005a). Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:-cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int. J. Cancer. 113, 189-197.
58. Stiborová, M., Frei, E., and Schmeiser, H. H. (2008c). Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int. 73, 1209-1211.
59. Stiborová, M., Frei, E., Sopko, B., Sopkova, K., Markova, V., Lankova, M., Kumstyrova, T., Wiessler, M., and Schmeiser, H. H. (2003a). Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H: quinone oxidoreductase. Carcinogenesis 24, 1695-1703.
60. Stiborová, M., Frei, E., Sopko, B., Wiessler, M., and Schmeiser, H. H. (2002a). Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23, 617-625.
61. Stiborová, M., Frei, E., Wiessler, M., and Schmeiser, H. H. (2001b). Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol. 14, 1128-1137.
62. Stiborová, M., Hájek, M., Frei, E., and Schmeiser, H. H. (2001c). Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH: cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen. Physiol. Biophys. 20, 375-392.
63. Stiborová, M., Mareš, J., Frei, E., Arlt, V. M., Martínek, V., and Schmeiser, H. H. (2011). The human carcinogen aristolochic acid I is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ. Mol. Mutagen.
64. Stiborová, M., Martinek, V., Rydlova, H., Hodek, P., and Frei, E. (2002b). Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 62, 5678-5684.
65. Stiborová, M., Martínek, V., Rýdlová, H., Koblas, T., and Hodek, P. (2005b). Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett. 220, 145-154.
66. Stiborová, M., Sejbal, J., Borek-Dohalska, L., Aimova, D., Poljakova, J., Forsterova, K., Rupertova, M., Wiesner, J., Hudecek, J., Wiessler, M., et al. (2004). The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide. Cancer Res. 64, 8374-8380.
67. Stiborová, M., Sopko, B., Hodek, P., Frei, E., Schmeiser, H. H., and Hudeček, J. (2005c). The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett. 229, 193-204.
68. Stiborová, M., Stiborová-Rupertová, M., Borek-Dohalská, L., Wiessler, M., and Frei, E. (2003b). Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem. Res. Toxicol. 16, 38-47.
69. Toncheva, D. I., von Ahsen, N., Atanasova, S. Y., Dimitrov, T. G., and Amstrong, V. M. (2004). Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J. Nephrol. 17, 384-389.
70. Tsuneoka, Y., Dalton, T. P., Miller, M. L., Clay, C. D., Shertzer, H. G., Talaska, G., Medvedovic, M., and Nebert, D. W. (2003). 4-aminobiphenylinduced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J. Natl. Cancer Inst. 95, 1227-1237.
71. Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., and Guengerich, F. P. (1997). Cooperativity in oxidation catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381.
72. Uno, S., Dalton, T. P., Derkenne, S., Curran, C. P., Miller, M. L., Shertzer, H. G., and Nebert, D. W. (2004). Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol. Pharmacol. 65, 1225-1237.
73. Vanherweghem, J. L., Depierreux, M., Tielemans, C., Abramowicz, D., Dratwa, M., Jadoul, M., Richard, C., Vandervelde, D., Verbeelen, D., Vanhaelen-Fastre, R., et al. (1993). Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341, 387-391.
74. Vondráček, J., Krcmár, P., Procházková, J., Trilecová, L., Gavelová, M., Skálová, L., Szotáková, B., Buncek, M., Radilová, H., Kozubík, A., et al. (2009). The role of aryl hydrocarbon receptor in regulation of enzymes involved in metabolic activation of polycyclic aromatic hydrocarbons in a model of rat liver progenitor cells. Chem. Biol. Interact. 180, 226-237.
75. Xiao, Y., Ge, M., Xue, X., Wang, C., Wang, H., Wu, X., Li, L., Liu, L., Qi, X., Zhang, Y., et al. (2008). Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 73, 1231-1239.
76. Xiao, Y., Xue, X., Wu, Y. F., Xin, G. Z., Qian, Y., Xie, T. P., Gong, L. K., and Ren, J. (2009). beta-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism. Acta Pharmacol. Sin. 30, 1559-1565.
77. Xue, X., Xiao, Y., Zhu, H., Wang, H., Liu, Y., Xie, T., and Ren, J. (2008). Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol. Dial. Transplant. 23, 3074-3081.